R&D | April 17, 2026
Revvity aims to accelerate breakthroughs in cancer research
Revvity is positioning its technologies as a connected engine for discovery
Revvity is positioning its technologies as a connected engine for discovery
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Subscribe To Our Newsletter & Stay Updated
